Literature DB >> 6224806

Inhibition of lymphocyte response by prostaglandin-producing suppressor cells in patients with melanoma.

J L Murray, G M Kollmorgen.   

Abstract

Peripheral blood mononuclear cells (PBMC) from 11 patients with metastatic melanoma (group II) had a significant decrease in blastogenesis to concanavalin A (Con A) (38.7 +/- 7.7 cpm X 10(3); mean +/- SE) compared to 21 patients who were disease free (70.6 +/- 6.7) or 16 healthy controls (83.6 +/- 10.3). If PBMC from patients were preincubated for 72 hr prior to exposure to mitogen, blastogenesis was restored to normal. In group II patients a similar improvement in reactivity of fresh PBMC occurred with indomethacin addition or following rigorous depletion of adherent monocytes. Supernatants from cells cultured with and without Con A in several group II patients contained very high levels of endogenous PGE2. Patients had a greater percentage of T lymphocytes bearing Fc receptors for ox erythrocytes (T gamma) than controls, which appeared to correlate with the increased sensitivity to suppression by exogenously added PGE2. These data suggest that the decreased blastogenesis in certain melanoma patients is due to an increase in PGE2 production by monocytes, along with an increase in lymphocyte sensitivity to its effects.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6224806     DOI: 10.1007/bf00915351

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  42 in total

1.  Inhibition of lymphocyte function in rats fed higher-fat diets.

Authors:  G M Kollmorgen; W A Sansing; A A Lehman; G Fischer; R E Longley; S S Alexander; M M King; P B McCay
Journal:  Cancer Res       Date:  1979-09       Impact factor: 12.701

2.  Abnormal monocyte chemotactic response in cancer patients.

Authors:  D A Boetcher; E J Leonard
Journal:  J Natl Cancer Inst       Date:  1974-04       Impact factor: 13.506

3.  Esterases in human leukocytes.

Authors:  C Y Li; K W Lam; L T Yam
Journal:  J Histochem Cytochem       Date:  1973-01       Impact factor: 2.479

4.  Depressed in vitro peripheral blood lymphocyte response to mitogens in cancer patients: the role of suppressor cells.

Authors:  M Zembala; B Mytar; T Popiela; G L Asherson
Journal:  Int J Cancer       Date:  1977-05-15       Impact factor: 7.396

5.  Partial reversal of the cellular immune defect in common variable immunodeficiency with indomethacin.

Authors:  J S Goodwin; A D Bankhurst; S A Murphy; D S Selinger; R P Messner; R C Williams
Journal:  J Clin Lab Immunol       Date:  1978-11

6.  Monocyte-produced prostaglandin induces Fc gamma receptor expression on human T cells.

Authors:  P A Kaszubowski; J S Goodwin
Journal:  Cell Immunol       Date:  1982-04       Impact factor: 4.868

7.  Suppressor thymus-derived lymphocytes in fungal infection.

Authors:  J D Stobo; S Paul; R E Van Scoy; P E Hermans
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

8.  Abnormalities of quantitative dinitrochlorobenzene sensitization in cancer patients: correlation with tumor stage and histology.

Authors:  W J Catalona; P B Chretien
Journal:  Cancer       Date:  1973-02       Impact factor: 6.860

9.  Suppressor cells in immunodepressed bladder and prostate cancer patients.

Authors:  H W Herr
Journal:  J Urol       Date:  1980-05       Impact factor: 7.450

10.  Subversion of immune system by tumor cells and role of prostaglandins.

Authors:  O J Plescia; A H Smith; K Grinwich
Journal:  Proc Natl Acad Sci U S A       Date:  1975-05       Impact factor: 11.205

View more
  2 in total

Review 1.  Prostaglandin E2 and T cells: friends or foes?

Authors:  Vinatha Sreeramkumar; Manuel Fresno; Natalia Cuesta
Journal:  Immunol Cell Biol       Date:  2011-09-27       Impact factor: 5.126

2.  Evidence for a role for interleukin-17, Th17 cells and iron homeostasis in protective immunity against tuberculosis in cynomolgus macaques.

Authors:  Alice S Wareham; Julia A Tree; Philip D Marsh; Philip D Butcher; Mike Dennis; Sally A Sharpe
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.